Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report

The present study reports the case of a 25-year-old male patient with salivary gland secretory carcinoma (SC) with the ETV6::RET gene fusion. The patient presented with a left parotid mass and was treated using a superficial parotidectomy. Histological analysis of the tumor demonstrated a combination of cystic, follicular and trabecular patterns in cells, with eosinophilic secretions and a vacuolated cytoplasm. Tumor cells exhibited infiltrative growth into muscle and nerve tissues, accompanied by central stromal hyalinized sclerosis. Immunohistochemically, the tumor cells were positive for S-100, mammaglobin and GATA binding protein 3, and negative for DOG1. The results of the present case demonstrated that the patient possessed SC with the ETV6::RET gene fusion. Following the operation, the patient underwent radiotherapy, leading to a disease-free state at the last follow-up at 1 year and 3 months following surgery. A comprehensive review of 21 SC cases with this gene fusion, including the case reported in the present study, demonstrated that invasive growth, neural and lymphovascular invasion and hyalinized sclerosis were frequently seen on histology, and 11 cases (52%) exhibited advanced-stage disease (>T3 or M1). Thus, salivary gland SC with an ETV6::RET fusion may show infiltrative growth and may be more aggressive compared with salivary gland SC with an ETV6::NTRK3 fusion, which is often associated with an indolent clinical course. Therefore, confirmation of the genetic profile of SC is crucial for the prediction of patient prognosis and administration of an effective therapeutic course.

Authors

Institutions

Publication Details

Journal
Biomedical Reports
Published
2025-02-21
DOI
https://doi.org/10.3892/br.2025.1951
Primary Topic
Salivary Gland Tumors Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report

Toshitaka Nagao, Yoshinobu Hirose, Masaaki Higashino, Tsuyoshi Jinnin et al.
1 links
Biomedical Reports
Salivary Gland Tumors Diagnosis and Treatment
article

Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report

Toshitaka Nagao, Yoshinobu Hirose, Masaaki Higashino, Tsuyoshi Jinnin, Emi Yasuda, Shin‐Ichi Haginomori, Hiroko Kuwabara, Akira Ishihara
article en

Abstract

The present study reports the case of a 25-year-old male patient with salivary gland secretory carcinoma (SC) with the ETV6::RET gene fusion. The patient presented with a left parotid mass and was treated using a superficial parotidectomy. Histological analysis of the tumor demonstrated a combination of cystic, follicular and trabecular patterns in cells, with eosinophilic secretions and a vacuolated cytoplasm. Tumor cells exhibited infiltrative growth into muscle and nerve tissues, accompanied by central stromal hyalinized sclerosis. Immunohistochemically, the tumor cells were positive for S-100, mammaglobin and GATA binding protein 3, and negative for DOG1. The results of the present case demonstrated that the patient possessed SC with the ETV6::RET gene fusion. Following the operation, the patient underwent radiotherapy, leading to a disease-free state at the last follow-up at 1 year and 3 months following surgery. A comprehensive review of 21 SC cases with this gene fusion, including the case reported in the present study, demonstrated that invasive growth, neural and lymphovascular invasion and hyalinized sclerosis were frequently seen on histology, and 11 cases (52%) exhibited advanced-stage disease (>T3 or M1). Thus, salivary gland SC with an ETV6::RET fusion may show infiltrative growth and may be more aggressive compared with salivary gland SC with an ETV6::NTRK3 fusion, which is often associated with an indolent clinical course. Therefore, confirmation of the genetic profile of SC is crucial for the prediction of patient prognosis and administration of an effective therapeutic course.

Biomedical ReportsVol. 22(4)
Tokyo Medical University (JP), Osaka University of Pharmaceutical Sciences (JP)
Zero hunger
Openalex Percentile: Top 94%
Salivary Gland Tumors Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.